Importantly, targeting the GAS6-TYRO3 axis in Myeloid-GAS6 KO mice sensitizes tumors to α-PD-1 therapy by enhancing CD8 + T cell infiltration and anti-tumor immunity, without inducing observable adverse effects, suggesting a promising and safe strategy to overcome resistance to immune checkpoint blockade in melanoma (Fig. 8E). The gene discussed is CD8A; the disease is neoplasm.